Literature DB >> 7199484

Clinical and laboratory predictors of clomiphene response.

R A Lobo, M Gysler, C M March, U Goebelsmann, D R Mishell.   

Abstract

A prospective study was carried out on 158 anovulatory women for the purpose of finding parameters that might predict the clomiphene dose at which ovulation would occur. Both body weight and obesity were positively correlated with the dose required to achieve ovulation (P less than 0.05). Once ovulation occurred, obesity did not affect the ability to conceive. Fifty-eight women who ovulated with various doses of clomiphene, including six women who failed to ovulate, had hormonal measurements performed prior to treatment. Compared with normally ovulating controls, serum luteinizing hormone (LH), the ratio of LH to follicle-stimulating hormone (FSH), serum androgens, unbound testosterone, and unbound estradiol were elevated and sex hormone binding globulin-binding capacity (SHBG-BC) significantly lower in women receiving clomiphene. Although the ovulatory dose of clomiphene was positively correlated with both weight and obesity, neither weight nor any laboratory parameter could accurately predict the clomiphene response.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7199484

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  19 in total

1.  Comparison of Nb2 lymphoma cell bioassay with immunoassay for human prolactin: the role of estrogen.

Authors:  S Nader; M D Warner; H G Friesen; C A Peabody
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

2.  Anovulation and ovulation induction.

Authors:  I Katsikis; M Kita; A Karkanaki; N Prapas; D Panidis
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

Review 3.  In vitro fertilization treatment in patients with polycystic ovaries.

Authors:  A Shulman; J Dor
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

4.  Resistin levels of serum and follicular fluid in non-obese patients with polycystic ovary syndrome during IVF cycles.

Authors:  Xiu-E Lu; He-Feng Huang; Mei-Gen Li; Yi-Min Zhu; Yu-Li Qiang; Min-Yue Dong
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

Review 5.  Polycystic ovarian disease (PCOD)--pregnancy rate and outcome in in vitro fertilization.

Authors:  D Bider; D Levran; S Mashiach; I Ben-Shlomo; J Dor
Journal:  J Assist Reprod Genet       Date:  1993-01       Impact factor: 3.412

Review 6.  Polycystic ovarian syndrome: diagnosis and management.

Authors:  Michael T Sheehan
Journal:  Clin Med Res       Date:  2004-02

7.  Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice.

Authors:  N D C Sturrock; B Lannon; T N Fay
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

8.  The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS.

Authors:  Papa Dasari; Gk Pranahita
Journal:  J Hum Reprod Sci       Date:  2009-01

Review 9.  Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS.

Authors:  Supat Sinawat; Pranom Buppasiri; Pisake Lumbiganon; Porjai Pattanittum
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

10.  Elevated body mass index (BMI) does not adversely affect in vitro fertilization outcome in young women.

Authors:  Kurt Martinuzzi; Sarah Ryan; Martha Luna; Alan B Copperman
Journal:  J Assist Reprod Genet       Date:  2008-04-19       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.